Westlake Village-based Cynvenio< Biosystems, a developer of technology for the molecular characterization of cancer, said this week that it has launched a new service aimed at helping to isolate, sequence, and enumerate circulating tumor cells. The firm said its new LiquidBiopsy Lab Service uses molecular characterization to identify the specific DNA mutations in cancer and circulating tumor cells, which will allow physicians and researchers to better understand the disease and monitor patients. The company said the availability of the service can help provide personalized medical treatments to patients.
Top NewsThursday, December 13, 2012
Cynvenio Debuts New Lab Service